- Posts by Elizabeth J. McEvoy
Member of the FirmAs a trusted advisor, advocate, and investigator, Elizabeth McEvoy guides clients through all stages of research compliance matters, such as research misconduct proceedings, federal grant compliance, and other highly ...
The U.S. Court of Appeals for the First Circuit recently provided important clarity—and welcome relief—for clinical laboratories facing False Claims Act (“FCA”) allegations based on a lack of medical necessity for processing tests ordered by a physician. In a case of first impression, United States ex rel. OMNI Healthcare, Inc. v. MD Spine Solutions LLC,[1] the First Circuit held that clinical laboratories may rely on an ordering physician’s determination that lab tests billed to Medicare are medically necessary. The First Circuit held that laboratories need not second-guess a physician’s certification absent red flags or suspected improper conduct. While the First Circuit’s decision does not relieve clinical laboratories of their existing obligation under the FCA to ensure they are not submitting a false claim to government payors, it provides much-needed clarity for clinical laboratories across the country on what constitutes the knowing submission of false claims to the government and highlights several practical takeaways for managing compliance risk.
Blog Editors
Recent Updates
- State AGs in Action: Health Care Enforcement in 2026 – Speaking of Litigation Video Podcast
- The DOJ’s New Corporate Enforcement Policy: A Familiar but Now Nationally Unified Framework for Voluntary Self-Disclosure
- The Case Was Settled, but ChatGPT Thought Otherwise: A Dispute Poised to Define AI Legal Liability
- “Claude Is Not an Attorney”: Individuals Risk Abandoning the Attorney-Client Privilege and Attorney Work-Product Doctrine When Consulting AI
- Prediction Markets v. State Gaming Laws: The Kalshi Litigation Gamble